Loading...
Loading...
Roundhill Investments launched a new exchange-traded fund (ETF) Tuesday . What Happened : The Roundhill GLP-1 & Weight Loss ETF OZEM marks a significant milestone as the world's first GLP-1 ETF. Roundhill asserts that weight loss drugs, particularly GLP-1 agonists, are among the most revolutionary advancements in the global pharmaceuticals industry.
Notably, OZEM is the only ETF providing dedicated exposure to transformative weight loss stocks such as Eli Lilly & Co. LLY , the producer of Zepbound, and Novo Nordisk A/S NVO , the maker of Ozempic. “These new treatments work incredibly well,” Roundhill CEO Dave Mazza told Benzinga.
Citing Goldman Sachs research, Mazza believes the market for weight loss drugs could expand more than 16 times its current size from its current $6 billion and reach $100 billion by 2030. Mazza compared the market dominance of Novo Nordisk and Eli Lilly in the weight loss drug sector to Nvidia Corp. ‘s NVDA position in generative AI.
Over 40% of the OZEM portfolio is invested in these two weight-loss drug leaders. “Those two names are in a league of their own as they have drugs currently in market. While we believe there's plenty of upside left in these names, there's more opportunities out there including companies that are in development with other drugs,” Mazza said.
For instance, Amgen Inc ‘s AMGN drug shows better results than bariatric surgery in just four weeks, and Viking Therapeutics Inc . VKTX is developing.
